Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

JX06, a Novel PDK1 Inhibitor, Induces Myeloma Cell Apoptosis By Metabolic Reprogramming and Works Synergistically with Bortezomib

Takayuki Sasano, Saki Kushima, Matsushita Yutaka, Masao Matsuoka, MD PhD, Hiroyuki Hata, MD PhD, Yawara Kawano, MD PhD

Blood (2019) 134 (Supplement_1): 1814.

https://doi.org/10.1182/blood-2019-123619

Published: 2019

Journal Articles

Inhibiting Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Induces Selective Leukemia Cell Death

Matthew Tcheng, BSc, Alessia Roma, BSc, Nawaz Ahmed, MSc, Richard Smith, PhD, Preethi Jayanth, PhD, Mark D. Minden, MD PhD, Rose Hurren, BSc, Aaron D Schimmer, MD PhD, Gale Bozzo, PhD, David Hess, PhD, Kristin Hope, PhD, Kevin Rea, MSc, Tariq A. Akhtar, PhD, Al-Walid Mohsen, PhD, Jerry Vockley, MD PhD, Paul A. Spagnuolo, PhD

Blood (2019) 134 (Supplement_1): 3922.

https://doi.org/10.1182/blood-2019-122262

Published: 2019

Journal Articles

Multicentre, Open Label, Randomized Phase III Study of Cpi-613 ® (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 years) with Relapsed / Refractory Acute Myeloid Leukemia (AML) - Armada 2000 (AML003) Trial

Timothy S. Pardee, MD PhD, Sanjeev Luther, MBA, Marc E. Buyse, ScD, Bayard L Powell, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2658.

https://doi.org/10.1182/blood-2019-129377

Published: 2019

Journal Articles

Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Effect of Age in Relapsed and Refractory AML

Timothy Pardee, MDPhD, Scott Isom, M.S., Leslie Renee Ellis, MD MSHPEd, Dianna S. Howard, MD, Rupali Bhave, MD, Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD

Blood (2018) 132 (Supplement 1): 1355.

https://doi.org/10.1182/blood-2018-99-118991

Published: 2018

Journal Articles

Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML

Timothy S Pardee, MD PhD, Scott Isom, M.S., Leslie Renee Ellis, MD, Dianna S. Howard, MD, Rupali Bhave, MD, Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD

Blood (2017) 130 (Supplement 1): 2626.

https://doi.org/10.1182/blood.V130.Suppl_1.2626.2626

Published: 2017

Journal Articles

Mitochondrial Carrier Homolog 2 (MTCH2) Regulates the Differentiation of AML Cells By Controlling Pyruvate Entry into the Mitochondria, Nuclear Localization of Pyruvate Dehydrogenase Complex and H3 and H4 Histone Acetylation

Dilshad H. Khan, Michael Mullokandov, Yan Wu, Marcela Gronda, MSc, Rose Hurren, BSc, Xiaoming Wang, Neil MacLean, Danny V. Jeyaraju, PhD, G. Wei Xu, Rob C. Laister, PhD, Zachary Blatman, Troy Ketela, Mark D. Minden, MD PhD, Atan Gross, PhD, Aaron D. Schimmer, MDPhD

Blood (2017) 130 (Supplement 1): 299.

https://doi.org/10.1182/blood.V130.Suppl_1.299.299

Published: 2017

Journal Articles

Glutamine Catabolism Maintains MCL-1 Expression in Glucose-Deprived Multiple Myeloma

Changyong Wei, PhD BS, Richa Bajpai, PhD, Alisha D Hunter, MS, Darius Mahboubi, MS, Mala Shanmugam, PhD

Blood (2017) 130 (Supplement 1): 3076.

https://doi.org/10.1182/blood.V130.Suppl_1.3076.3076

Published: 2017

Journal Articles

Pyruvate Dehydrogenase Kinase Modulates Platelet Function and Thrombosis

Manasa Nayak, PhD, Nirav Dhanesha, PhD, Vijay Sonkar, PhD, Sanjana Dayal, PhD, Anil Chauhan, PhD

Blood (2017) 130 (Supplement 1): 2389.

https://doi.org/10.1182/blood.V130.Suppl_1.2389.2389

Published: 2017

Journal Articles

Pyruvate Dehydrogenase (PDH) Activity Is a Source of Resistance to Sorafenib in FLT3-ITD Expressing Acute Myeloid Leukemia (AML)

Rebecca G. Anderson, B.S., Kristin M. Pladna, M.S., Timothy S Pardee, MD PhD

Blood (2017) 130 (Supplement 1): 3829.

https://doi.org/10.1182/blood.V130.Suppl_1.3829.3829

Published: 2017

Journal Articles

Remodeling Ca 2+ Flux By ORP4L Is Essential for Leukemia Stem Cells (LSCs) Survival

Wenbin Zhong, Vesa Olkkonen, Xu Bing, Biying Zhu, Guoping Li, Jian Li, Qing Yi, Daoguang Yan

Blood (2016) 128 (22): 5257.

https://doi.org/10.1182/blood.V128.22.5257.5257

Published: 2016

Journal Articles

Type B Lactic Acidosis in Advanced Diffuse Large B-Cell Lymphoma

Nancy El-Shamaa Kaddis, MD MPH

Blood (2016) 128 (22): 5420.

https://doi.org/10.1182/blood.V128.22.5420.5420

Published: 2016

Journal Articles

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Lance D Miller, PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA-C, Bayard L Powell, MD

Blood (2016) 128 (22): 4062.

https://doi.org/10.1182/blood.V128.22.4062.4062

Published: 2016

Journal Articles

Targeting Glycolysis and MAPK Pathway: A Combined Pre-Clinical Approach on Acute Myeloid Leukemia

Simone Mirabilii, PhD, Maria Rosaria Ricciardi, PhD, Roberto Licchetta, M.Sc., Maria Paola Bianchi, MD, Monica Piedimonte, MD, Agostino Tafuri, MD

Blood (2016) 128 (22): 2751.

https://doi.org/10.1182/blood.V128.22.2751.2751

Published: 2016

Journal Articles

Targeting Redox Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma

Nathan G. Dolloff, PhD, Leticia Reyes, Brittany Smith, John Fairbanks Langenheim, PhD, Yefim Manevich

Blood (2015) 126 (23): 1819.

https://doi.org/10.1182/blood.V126.23.1819.1819

Published: 2015

Journal Articles

The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)

Timothy Pardee, MD PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, David D Hurd, MD, Susan Lyerly, PA-C, Bayard L Powell, MD

Blood (2015) 126 (23): 2556.

https://doi.org/10.1182/blood.V126.23.2556.2556

Published: 2015

Journal Articles

Novel Nanomolar Potency Mitochondrial Complex I Inhibitor Iacs-1131 Selectively Kills Oxphos-Dependent AML Cells

Polina Matre, PhD, Marina Protopopova, Ningping Feng, Jason Gay, Jennifer Greer, Juliana Velez, Hong Mu, MD PhD, Alessia Lodi, Surendar Tadi, Shannon Sweeney, Michael Andreeff, MD PhD, Stefano Tiziani, M. Emilia DiFrancesco, Joseph Marszalek, Marina Konopleva, MD PhD

Blood (2014) 124 (21): 622.

https://doi.org/10.1182/blood.V124.21.622.622

Published: 2014

Journal Articles

The Mitochondrial Metabolism Inhibitor Cpi-613 Is Highly Active in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone in a Phase I Study for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Kristin Stadelman, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, David D Hurd, MD, Robin Harrelson, BSN, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA, Bayard L. Powell, MD

Blood (2014) 124 (21): 3744.

https://doi.org/10.1182/blood.V124.21.3744.3744

Published: 2014

Journal Articles

Synergistic Antileukemic Effect Of Sequential Administration Of Dichloroacetate (DCA) Combined With Arsenic Trioxide (ATO) In Primary Blasts From Patients With Acute Myeloid Leukemia (AML) and FLT3-ITD AML Cell Lines

Ashkan Emadi, M.D., Ph.D., Brandon Carter-Cooper, BS, Mariola Sadowska, PhD, Omasiri Wonodi, BS, Rena G. Lapidus, PhD, Mark Levis, MD, PhD, Edward A. Sausville, MD, PhD

Blood (2013) 122 (21): 3955.

https://doi.org/10.1182/blood.V122.21.3955.3955

Published: 2013

Journal Articles

Ph-Negative Myeloproliferative Neoplasms Exhibit Some Features Of Warburg Effect

Sherjeel Sana, MD, Maria Navas-Mareno, PhD, Z.Valey Vardney, PhD, Mark Duros, MS, Felipe R Lorenzo V, PhD, Katarina Kapralova, MSc, Sabina Swierczek, PhD, Josef Prchal, MD

Blood (2013) 122 (21): 1604.

https://doi.org/10.1182/blood.V122.21.1604.1604

Published: 2013

Journal Articles

Cited2 Is Required For The Maintenance Of Glycolytic Metabolism In Adult Hematopoietic Stem Cells

Jinwei Du, PhD, Qiang Li, PhD, Fangqiang Tang, PhD, Michelle Puchowitz, PhD, Hasashi Fujioka, PhD, Sally Dunwoodie, PhD, David Danielpour, PhD, Yu-Chung Yang, PhD

Blood (2013) 122 (21): 794.

https://doi.org/10.1182/blood.V122.21.794.794

Published: 2013

NARROW

JX06, a Novel PDK1 Inhibitor, Induces Myeloma Cell Apoptosis By Metabolic Reprogramming and Works Synergistically with Bortezomib

Inhibiting Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Induces Selective Leukemia Cell Death

Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Effect of Age in Relapsed and Refractory AML

Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML

Mitochondrial Carrier Homolog 2 (MTCH2) Regulates the Differentiation of AML Cells By Controlling Pyruvate Entry into the Mitochondria, Nuclear Localization of Pyruvate Dehydrogenase Complex and H3 and H4 Histone Acetylation

Glutamine Catabolism Maintains MCL-1 Expression in Glucose-Deprived Multiple Myeloma

Pyruvate Dehydrogenase Kinase Modulates Platelet Function and Thrombosis

Pyruvate Dehydrogenase (PDH) Activity Is a Source of Resistance to Sorafenib in FLT3-ITD Expressing Acute Myeloid Leukemia (AML)

Remodeling Ca 2+ Flux By ORP4L Is Essential for Leukemia Stem Cells (LSCs) Survival

Type B Lactic Acidosis in Advanced Diffuse Large B-Cell Lymphoma

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

Targeting Glycolysis and MAPK Pathway: A Combined Pre-Clinical Approach on Acute Myeloid Leukemia

Targeting Redox Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma

The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)

Novel Nanomolar Potency Mitochondrial Complex I Inhibitor Iacs-1131 Selectively Kills Oxphos-Dependent AML Cells

The Mitochondrial Metabolism Inhibitor Cpi-613 Is Highly Active in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone in a Phase I Study for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Synergistic Antileukemic Effect Of Sequential Administration Of Dichloroacetate (DCA) Combined With Arsenic Trioxide (ATO) In Primary Blasts From Patients With Acute Myeloid Leukemia (AML) and FLT3-ITD AML Cell Lines

Ph-Negative Myeloproliferative Neoplasms Exhibit Some Features Of Warburg Effect

Cited2 Is Required For The Maintenance Of Glycolytic Metabolism In Adult Hematopoietic Stem Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only